Multi-drug-resistant tuberculosis future or investigational therapies

Multi-drug-resistant tuberculosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Multi-drug-resistant tuberculosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Multi-drug-resistant tuberculosis future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Multi-drug-resistant tuberculosis future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Multi-drug-resistant tuberculosis future or investigational therapies
CDC on Multi-drug-resistant tuberculosis future or investigational therapies
Multi-drug-resistant tuberculosis future or investigational therapies in the news
Blogs on Multi-drug-resistant tuberculosis future or investigational therapies
Directions to Hospitals Treating Multi-drug-resistant tuberculosis
Risk calculators and risk factors for Multi-drug-resistant tuberculosis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Since new drug resistant tuberculosis have been emerging, the role of future therapies is vital in curbing outbreaks. The new drugs should be more effective than the current regimen and a few drugs in clinical trials have been showing good results.

Future investigations

Principles of future investigations

Any future regimen should satisfy the following principles.

• It should not have more than a maximum duration of 6 months
• The dosing schedule must be simple
• The number of drugs in it should be ideally not more than 3-5 drug each from a different class
• It should have minimum side effect profile so that we could have minimum monitoring
• It should be effective against MDR, XDR and XXDR strains
• It should be administered per orally
• It should have minimum interaction with anti retroviral drugs.
• It should have atleast one new class of drug

New drugs involved in clinical trial for treatment of tuberculosis

Drug	Phase	Class
Moxifloxacin	Phase III	Fluoroquinolone
Linezolid	Phase II	Oxazolidinone
AZD-5847	Phase II	Oxazolidinone
Sutezolid	Phase II	Oxazolidinone
Clofazimine	Phase II	Riminophenazine
SQ-109	Phase II	Ethylenediamine
PA-824	Phase IIb	Nitroimidazole
Delamanid	Phase III	Nitroimidazole
Bedaquiline	Phase III	Diarylquinoline
Data provided by WHO